Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation

THE WOODLANDS, TX, July 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced positive results from a preclinical study demonstrating the ability of its proprietary neural sensing platform to detect, localize and confirm changes in renal neural activity.